These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36033396)

  • 21. Plasma-Derived Extracellular Vesicles as Potential Biomarkers in Heart Transplant Patient with Chronic Chagas Disease.
    Cortes-Serra N; Mendes MT; Mazagatos C; Segui-Barber J; Ellis CC; Ballart C; Garcia-Alvarez A; Gállego M; Gascon J; Almeida IC; Pinazo MJ; Fernandez-Becerra C
    Emerg Infect Dis; 2020 Aug; 26(8):1846-1851. PubMed ID: 32687028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The protein family TcTASV-C is a novel Trypanosoma cruzi virulence factor secreted in extracellular vesicles by trypomastigotes and highly expressed in bloodstream forms.
    Caeiro LD; Alba-Soto CD; Rizzi M; Solana ME; Rodriguez G; Chidichimo AM; Rodriguez ME; Sánchez DO; Levy GV; Tekiel V
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006475. PubMed ID: 29727453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug discovery for chagas disease: A viewpoint.
    Kratz JM
    Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.
    Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ
    Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi Infection.
    de Morais CG; Castro Lima AK; Terra R; dos Santos RF; Da-Silva SA; Dutra PM
    Biomed Res Int; 2015; 2015():324915. PubMed ID: 26090399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Analysis of the Secretome and Interactome of
    Watanabe Costa R; Batista MF; Meneghelli I; Vidal RO; Nájera CA; Mendes AC; Andrade-Lima IA; da Silveira JF; Lopes LR; Ferreira LRP; Antoneli F; Bahia D
    Front Immunol; 2020; 11():1774. PubMed ID: 32973747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
    Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
    Front Immunol; 2020; 11():565142. PubMed ID: 33162979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
    Basso B; Marini V
    Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease.
    Junqueira C; Caetano B; Bartholomeu DC; Melo MB; Ropert C; Rodrigues MM; Gazzinelli RT
    Expert Rev Mol Med; 2010 Sep; 12():e29. PubMed ID: 20840799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.
    Serna C; Lara JA; Rodrigues SP; Marques AF; Almeida IC; Maldonado RA
    Vaccine; 2014 Jun; 32(28):3525-32. PubMed ID: 24793944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine Against
    Gamba JC; Roldán C; Prochetto E; Lupi G; Bontempi I; Poncini CV; Vermeulen M; Pérez AR; Marcipar I; Cabrera G
    Front Cell Infect Microbiol; 2021; 11():671104. PubMed ID: 34295832
    [No Abstract]   [Full Text] [Related]  

  • 32. Comprehensive glycoprofiling of the epimastigote and trypomastigote stages of Trypanosoma cruzi.
    Alves MJ; Kawahara R; Viner R; Colli W; Mattos EC; Thaysen-Andersen M; Larsen MR; Palmisano G
    J Proteomics; 2017 Jan; 151():182-192. PubMed ID: 27318177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of α-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcomes of Chagas Disease.
    Ortega-Rodriguez U; Portillo S; Ashmus RA; Duran JA; Schocker NS; Iniguez E; Montoya AL; Zepeda BG; Olivas JJ; Karimi NH; Alonso-Padilla J; Izquierdo L; Pinazo MJ; de Noya BA; Noya O; Maldonado RA; Torrico F; Gascon J; Michael K; Almeida IC
    Methods Mol Biol; 2019; 1955():287-308. PubMed ID: 30868536
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Trevisan RO; Santos MM; Desidério CS; Alves LG; de Jesus Sousa T; de Castro Oliveira L; Jaiswal AK; Tiwari S; Bovi WG; de Oliveira-Silva M; Costa-Madeira JC; Castellano LRC; Silva MV; Azevedo V; Rodrigues Junior V; Oliveira CJF; de Castro Soares S
    Dis Markers; 2020; 2020():9130719. PubMed ID: 33488847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humoral and cellular immune response of adults from northeastern Brazil with chronic Trypanosoma cruzi infection: depressed cellular immune response to T. cruzi antigen among Chagas' disease patients with symptomatic versus indeterminate infection.
    Cetron MS; Basilio FP; Moraes AP; Sousa AQ; Paes JN; Kahn SJ; Wener MH; Van Voorhis WC
    Am J Trop Med Hyg; 1993 Sep; 49(3):370-82. PubMed ID: 8372959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection.
    Barry MA; Versteeg L; Wang Q; Pollet J; Zhan B; Gusovsky F; Bottazzi ME; Hotez PJ; Jones KM
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007413. PubMed ID: 31145733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic flux of microvesicles modulate parasite-host cell interaction of Trypanosoma cruzi in eukaryotic cells.
    Ramirez MI; Deolindo P; de Messias-Reason IJ; Arigi EA; Choi H; Almeida IC; Evans-Osses I
    Cell Microbiol; 2017 Apr; 19(4):. PubMed ID: 27665486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different Transcriptomic Response to
    Oliveira TGM; Venturini G; Alvim JM; Feijó LL; Dinardo CL; Sabino EC; Seidman JG; Seidman CE; Krieger JE; Pereira AC
    Front Cell Infect Microbiol; 2022; 12():904747. PubMed ID: 35873155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against
    Antonoglou MB; Sánchez Alberti A; Redolfi DM; Bivona AE; Fernández Lynch MJ; Noli Truant S; Sarratea MB; Iannantuono López LV; Malchiodi EL; Fernández MM
    Front Immunol; 2020; 11():1279. PubMed ID: 32695105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative stress implications for therapeutic vaccine development against Chagas disease.
    Choudhuri S; Rios L; Vázquez-Chagoyán JC; Garg NJ
    Expert Rev Vaccines; 2021 Nov; 20(11):1395-1406. PubMed ID: 34406892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.